AOD-9604 Side Effects: What Researchers Need to Know

AOD-9604 (Advanced Obesity Drug 9604) is a synthetic peptide corresponding to the C-terminal fragment of human growth hormone, specifically amino acids 176–191, with a tyrosine residue added at the N-terminus. It was originally developed to isolate the lipolytic (fat-burning) properties of GH from its growth-promoting effects.

Clinical trials have investigated AOD-9604 primarily in the context of obesity and fat metabolism. It has also received regulatory attention — notably, the Australian TGA granted it Generally Recognized As Safe (GRAS) status for use in food products in limited contexts.

AOD-9604 is available for research purposes only and is not FDA-approved for weight loss or any therapeutic indication.

AOD-9604 has demonstrated a favorable safety profile in clinical studies. The most commonly reported side effects include:

Importantly, unlike full-length growth hormone, AOD-9604 has not been shown to cause hyperglycemia, insulin resistance, or increased IGF-1 levels in clinical trials — a significant safety advantage.

Serious side effects from AOD-9604 are rare, but the following have been noted or warrant theoretical consideration:

• Allergic reactions: As with any injectable peptide, hypersensitivity reactions including rash, swelling, and in very rare cases, anaphylaxis are possible.
• Chest tightness or palpitations: Rare reports exist, though these have not been definitively attributed to AOD-9604 in controlled settings.
• Hypothalamic-pituitary effects: While AOD-9604 is designed to avoid GH receptor activation, high doses could theoretically interact with growth hormone feedback pathways.
• Gastrointestinal discomfort: Some subjects in clinical trials reported stomach cramps or indigestion, particularly at higher doses.

Phase II clinical trials involving over 300 subjects did not identify any serious adverse events attributable to AOD-9604, supporting its favorable safety profile.

To reduce the likelihood of adverse reactions in AOD-9604 research protocols:

• Administer on an empty stomach: AOD-9604 is typically studied in fasting conditions to optimize absorption and reduce gastrointestinal effects.
• Use subcutaneous injection: The subcutaneous route is standard and produces fewer systemic side effects than other administration methods.
• Start at conservative doses: Begin with lower doses and titrate up as tolerated, following established clinical trial protocols.
• Rotate injection sites: This reduces localized pain and irritation.
• Source high-purity product: Impurities in peptide preparations are a major source of injection site reactions and unexpected adverse effects.

The following symptoms during AOD-9604 use warrant immediate medical consultation:

• Signs of severe allergic reaction (throat swelling, hives, breathing difficulty)
• Chest pain, rapid heartbeat, or palpitations
• Severe or persistent abdominal pain
• Unusual swelling in extremities
• Any symptom that is unexpected, persistent, or worsening

Thorough documentation of all adverse events is essential for responsible research practice.

Because AOD-9604 is a modified peptide fragment, synthesis quality significantly impacts both efficacy and safety. Incomplete or incorrect modifications can produce byproducts that cause adverse reactions unrelated to AOD-9604 itself.

Ascension Peptides is our recommended source for research-grade AOD-9604. They provide 99%+ purity confirmed by independent HPLC and mass spectrometry analysis, with batch-specific COAs and proper handling throughout the supply chain.

Always verify the molecular identity and purity of AOD-9604 via COA before use in any research protocol.

AOD-9604 is sold for research purposes only and is not intended for human consumption. This content is for informational purposes only and does not constitute medical advice.